Mini review · 2017
Research articlePublished 2012
MITF Expression in Cutaneous Malignant Melanoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The MITF protein has a central role in the differentiation and survival of melanocytes. The aim of the study was to investigate whether MITF can be employed as a prognostic marker in patients operated on for cutaneous malignant melanoma. A cohort study design, based on information collected from population-based registries, was employed. For included patients (n=264) tissue microarrays were stained with immunohistochemistry to study the protein expression of MITF in primary malignant melanoma tumors by estimating the fraction of positive tumor cells and the staining intensity. Most of the tumors (84%) expressed MITF in >25% of the tumor cells and for 87% of the tumors the staining intensity was strong. Tumors with cell fraction >75% had a better prognosis compared with those with <75% (HR 0.44, 95% CI: 0.20-1.0, P=0.05). Tumors with a strong staining intensity tended to have a better prognosis compared with the weaker staining ones (HR 0.59, 95% CI: 0.26 -1.36, P=0.22). When cell fraction and intensity were combined, a high-risk group dying of malignant melanoma was identified as those patients with 25- 75% of tumor cells staining with weak intensity (HR 2.9, 95% CI: 0.94-8.7, P=0.06) and those with <25% of tumor cells staining with strong intensity (HR 2.5, 95% CI: 1.1- 6.1, P=0.04). However, the majority of deaths occurred in the lower risk groups. In conclusion, a high-risk group for death in malignant melanoma was identified but MITF is not suitable as a prognostic marker due to the distribution of that particular expression in the population.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 2014
Low Frequency of Germline TERT and MITF Mutations in Brazilian Melanoma- Prone Patients
Research article · 2017
Evaluation of Immunostaining for 4-Hydroxy-2-Nonenal Receptors in Cutaneous Malignant Melanoma Immunohistochemical Study of 55 Cases
Research article · 15 Jun 2017
A validation study for the use VE1 immunohistochemical staining in screening for BRAF mutation in cutaneous malignant melanoma
Research article · 2013
GSTM1 Null Genotype is Associated with an Increased Risk of Cutaneous Malignant Melanoma in the Japanese Population
More from this journal
The newest in Journal of Molecular Biomarkers & Diagnosis.
Brief report · 29 Dec 2025
Biomarker Discovery To Clinical Translation: A Holistic Approach
Commentary · 29 Dec 2025
Molecular Diagnostics: Revolutionizing Precision Healthcare
Commentary · 29 Dec 2025
Genomic Biomarkers Revolutionizing Disease Diagnosis and Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Margrét Agnarsdóttir”
- BylineArticles whose byline prints “Fredrik Ponten”
- BylineArticles whose byline prints “Hans Garmo”
- BylineArticles whose byline prints “Gunnar Wagenius”
- BylineArticles whose byline prints “Lorelei Mucci”
- BylineArticles whose byline prints “Kristina Magnusson”
- BylineArticles whose byline prints “Lars Holmberg”
- BylineArticles whose byline prints “Sonja Eaker-Fält”

